NON-EXCLUSIVE LICENSE AGREEMENT

**THIS NON-EXCLUSIVE LICENSE AGREEMENT (**the **“Agreement”)** is made and entered into, as of the last of the dates shown in the signature block below (“**Effective Date**”) by and between the Washington University, a corporation established by special act of the Missouri General Assembly approved February 22, 1853 and acts amendatory thereto, having its principal offices at One Brookings Drive, St. Louis, Missouri 63130 (hereinafter referred to as "WU"); and \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_, a corporation of the State of \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_, having a place of business at \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ (hereinafter referred to as "Licensee"), each a “Party” or collectively the “Parties” of this Agreement.

**RECITALS**

WHEREAS, WU, by virtue of its role as an educational institution, carries out scientific research through its faculty, staff, and students, and is committed to bringing the results of that research into widespread use;

WHEREAS, WU has developed technical information, related data and intellectual property in the field of disease risk assessments, and is owner of certain intellectual property rights which can be applied to that field, and has the right to grant licenses to said intellectual property, subject to rights reserved to the United States Government under 35 U.S.C. § 200, *et seq*., and regulations;

WHEREAS, Licensee desires to license said technical information, related data and intellectual property for its own use; and

WHEREAS, WU is willing and entitled to license technical information, related data and intellectual property to Licensee for the purpose mentioned above.

**TERMS AND CONDITIONS**

# NOW, THEREFORE, in consideration of the premises, covenants and agreements set forth herein and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows:

# DEFINITIONS

* 1. **“Authorized Use”** means Licenee’s the use of WU Intellectual Property solely in connection with the not-for-profit use described in Exhibit C (the “Protocol”), herin incorporated as a part of this Agreement.
	2. “**Excluded Authorized Use**”means any use of WU Intellectual Property by or through Licensee which i) meets any criteria outlined in Exhibit B herein, ii) contains information and provides disease assessments not included within the Authorized Use, and/or records and retains information that would allow for the identification of an end-user of Disease Risk Assessment Tools.”
	3. **“Disease Risk Assessment Tools”** means products and services created by Licensee that incorporate and/or utilize the WU Intellectual Property and/or Derivative Works to calculate an individual’s disease risk.
	4. **“Derivative Works”** means any modification to the WU Intellectual Property by Licensee.
	5. **“WU Intellectual Property”** means the technical information, related data and intellectual property identified in Exhibit A. For the avoidance of doubt, WU Intellectual Property shall not include any Supplemental IP.
	6. **“Supplemental IP”** means any additional intellectual property from third party vendors required for the WU Intellectual Property to function and be utilized.
	7. **“Your Disease Risk Web Site”** shall mean the yourdiseaserisk.com web site that includes certain content, software and other technology owned by WU which allows users of the web site to gain (i) information about their risk of having certain diseases, including but not limited to certain cancers, based on scientific evidence of certain disease risk factors and based on personal information provided by them, and (ii) general information regarding risks and preventions associated with specific types of disease, including but not limited to specific cancers.
1. **LICENSE GRANTS AND RESTRICTIONS**
	1. **Grant of License.**  WU, subject to the limitations and conditions set forth herein, grants to Licensee a fee-bearing, non-exclusive, non-commercial, non-transferable license to use, copy, and modify the WU Intellectual Property for use in connection with the Authorized Use and for no other purpose. WU further grants to Licensee, and Licensee hereby accepts, the right to allow Licensee’s service providers to make modifications to the WU Intellectual Property for Licensee’s use in connection with the Authorized Use and for no other purpose, provided that Licensee ensures that the service provider agree, in writing, to provisions no less stringent than as described in this Agreement, and provided further that Licensee’s service providers shall not be allowed to further distribute the WU Intellectual Property. Any act, error or omission of Licensee’s service provider that would be a breach of this Agreement if imputed to Licensee will be deemed to be a breach of this Agreement by Licensee. For the avoidance of doubt, such license shall not include a license to any Supplemental IP, and Licessee is strictly prohibited from using, copying, or modifying the WU Intellectual Property for use in connection with the Excluded Authorized Use.
	2. **Reservation of Rights and Restrictions.** Nothing in this Agreement provides Licensee with any ownership rights of any kind in the WU Intellectual Property. All ownership rights in the WU Intellectual Property shall remain the sole and exclusive property of WU. No license or right is granted by WU, by implication or otherwise, to any intellectual property other than the WU Intellectual Property. Other than the license expressly granted in Section 2.1 above, all rights in and to the WU Intellectual Property are hereby reserved by WU. Licensee agrees not to use the WU Intellectual Property or do any act in respect thereof outside the scope of the license expressly granted above including, without limitation, providing any WU Intellectual Property to any third party. Licensee further agrees that it will not do any act or thing which would in any way contest WU’s ownership in, or otherwise derogate from the ownership by WU, of any rights in the WU Intellectual Property. In furtherance of the foregoing but without limiting the generality thereof, Licensee agrees not to register or attempt to register any rights in the WU Intellectual Property or to assist any third party to do so.
	3. **Derivative Works.** Licensee will have the right to modify the WU Intellectual Property solely for the purpose of maximizing the functionality of the WU Intellectual Property for use in connection with the Authorized Use. Any such modifications to the WU Intellectual Property by or on behalf of Licensee ("**Derivative Works**") will be owned by WU. For clarification, Disease Risk Assessment Tools will not be owned by WU. WU will, however, retain ownership of WU Intellectual Property and Derivative Works incorporated into Disease Risk Assessment Tools. Licensee will notify WU promptly of the creation of any Derivative Works, and will provide a copy of the Derivative Work with such notification. Licensee hereby assigns all U.S. and other foreign rights, including all copyrights and rights of authorship in the Derivative Work to WU and agrees to execute any and all documents and agreements necessary to effectuate such assignment and registration and protection of such rights. WU hereby grants to Licensee and Licensee hereby accepts, a non-transferable, non-exclusive, fully paid up license for the term of this Agreement to copy, modify, and use the Derivative Works for use solely in connection with the Authorized Use, upon receipt of the above-described notification. Licensee understands and agrees that the rights to the Derivative Work do not supersede Licensee's obligation to protect the confidentiality of the WU Intellectual Property, nor do rights to Derivative Works in any way expand the license to the WU Intellectual Property granted hereunder. Licensee may not distribute any Derivative Work to any third party without the express written permission of WU. For the avoidance of doubt, Licensee’s rights under this Section 2.3 do not include any right to copy, modify, distribute, or publicly display any products or services for any commercial purpose. WU agrees to negotiate in good faith with Licensee regarding Licensee’s use of Derivative Works for commercial purposes.
2. **LICENSE FEE**
	1. **Licensee Issue Fee.** In consideration for the license granted hereunder, Licensee will pay to WU a one-time fee of two thousand dollars ($2,000) per year, due within thiry (30) days after the Effective Date (“**License Issue Fee**”). Such License Fee shall be non-refundable and shall not be credited against any other payment that may be due hereunder.
	2. **License Maintenance Fee.** In consideration for the license granted hereunder, to continue annually, Licensee will pay to WU a sum of two thousand dollars ($2,000) per year, due within thirty (30) days after each year-anniversary of the Effective Date (“**License Maintenance Fee**”). All License Maintenance Fees shall be non-refundable and not be credited against any other payment that may be due hereunder.
	3. **Method of Payment.** All dollar ($) amounts referred to in this Agreement are expressed in United States dollars. All payments to WU shall be made in United States dollars by check or electronic transfer payable to "Washington University."
	4. **Place of Payment.** Checks shall reference WU Contract Number 007671-00\_\_ and shall be sent to:

 Washington University

 Office of Technology Management

Washington University in St. Louis

660 South Euclid Avenue, CB 8013

St. Louis, MO 63110

All payments shall include the WU Contract Number to ensure accurate crediting to Licensee’s account. Electronic transfers shall be made to a bank account designated in writing by WU.

* 1. **Taxes.** WU shall have no liability for any sales, use, service, occupation, excise, gross receipts, income, property or other taxes or assessments (“Taxes”), whether levied upon Licensee, Licensee’s property, or upon WU, in connection with the License Fee (except any taxes WU is required by law to collect from Licensee with respect to the License Fee and/or License Maintenance Fee, such as sales taxes). Payment of all such taxes shall be the responsibility of Licensee, and if Licensee is required to withhold any such Taxes, the License Fee and/or License Maintenance Fee shall be adjusted upward to take into consideration such withholding such that the net amount remitted to WU equals the License Fee and/or License Maintenance Fee otherwise payable had there been no such withholding.
	2. **Interest and Collection.** Any amounts not paid by Licensee to WU when due shall accrue interest, from the date thirty (30) days after the balance is due at an interest rate of 1.5% per month or portion of a month. In addition, Licensee will reimburse WU for all reasonable costs and expenses incurred (including reasonable attorneys’ fees) in collecting any overdue amounts.
	3. **Condition to Grant.** Licensee understands and acknowledges that payment of the License Fee and/or License Maintenance Fee is a condition precedent to the grant of the license described herein, and that if Licensee fails to pay the License Fee and/or License Maintenance Fee when due, the license granted in this Agreement will terminate immediately.

# Confidentiality

# Confidential Information. Licensee agrees to hold in confidence all Confidential Information disclosed under this Agreement. The term “Confidential Information” means (i) the WU Intellectual Property, including, but not limited to, algorithms, computer code (both source code and object code), designs, (ii) documentation, instruction and training manuals, diagrams, flow charts, and business processes, whether or not identified as “proprietary,” “secret,” or “confidential” and (iii) all other information disclosed by WU to Licensee, which, if in writing or in electronic or other tangible form, bears a “secret,” “confidential,” or other similar designation or, if communicated orally, is followed up with a written memorandum describing the information so disclosed and the circumstances of disclosure and asserting a claim of confidentiality with respect thereto. Licensee acknowledges that the Confidential Information is the sole and exclusive property of WU.

# Exclusions. Confidential Information does not include information that (a) was known to Licensee prior to receipt from the WU as evidenced by the receiving Party’s records; (b) is or becomes part of the public domain through no act by or on behalf of Licensee; (c) is lawfully received by the Licensee from a third party without any restrictions, and/or (d) comprises identical subject matter to that which had been originally and independently developed by Licensee personnel without knowledge or use of any Confidential Information as evidenced by Licensee records.

# General Obligations. Licensee agrees that for the term of this Agreement and for a period of ten (10) years thereafter, it will (a) refrain from disclosing any Confidential Information to third parties, (b) disclose Confidential Information to only those employees of Licensee necessary for the receiving Party to use the Confidential Information in accordance with this Agreement and who are subject to restrictions on use and disclosure at least as restrictive as those set forth in this Agreement, (c) keep confidential the Confidential Information, and (d) except for use in accordance with the licenses which are expressly granted in this Agreement, refrain from using Confidential Information.

# Judicial Procedures. Licensee may, to the extent necessary, disclose Confidential Information in accordance with a judicial or other governmental order, provided that Licensee either (a) gives WU reasonable notice prior to such disclosure to allow the WU a reasonable opportunity to seek a protective order or equivalent, or (b) obtains written assurance from the applicable judicial or governmental entity that it will afford the Confidential Information the highest level of protection afforded under applicable law or regulation.

# NO CONTEST

* 1. Licensee shall not itself challenge or contest nor cooperate with or furnish assistance to any person, firm, or corporation who challenges or contests the validity of the intellectual property rights of WU with respect to the WU Intellectual Property or the Confidential Information or WU’s sole and exclusive right, title, and interest in and to the WU Intellectual Property and Confidential Information.

# SUB-LICENSE AND ASSIGNMENT

# Neither the license granted hereunder, nor the WU Intellectual Property or any part thereof may be sub-licensed, assigned, transferred or given away by Licensee without the prior written consent of WU. Any attempt to sub-license, assign or transfer any of the rights, interests, duties or obligations under this Agreement constitutes a material breach of this Agreement justifying termination, and any such attempted transfer will be null and void.

# 7. Copying

# 7.1 Other than as expressly provided under this Agreement,

# Licensee shall not, under any circumstances, directly or indirectly, copy, modify, decompile, or reverse engineer all or any part of the WU Intellectual Property.

# Required Notices

**8.1** Licensee shall not remove any copyright notice or trade secret legend from any copy of the WU Intellectual Property or other Confidential Information, and the Licensee shall not assert and shall not represent to any third party that it has any ownership rights in, or the right to sell, transfer, assign or sub-license the WU Intellectual Property**.** In Further, Disease Risk Assessment Tools shall not include any reference to the WU Intellectual Property, WU and/or the creators of the WU Intellectual Property.

# 9. This section intentionally left blank

# 10. Technical Support

**10.1** The Parties understand and agree that, under this Agreement, WU has not agreed to provide any maintenance or support services with respect to the WU Intellectual Property, nor has WU agreed to update, upgrade, or provide new versions, releases of, “fixes” for, or “security patches” to the WU Intellectual Property.

**11. Representations and Warranties**

**11.1** **Authority.** Each of WU and Licensee represents and warrants to the other of them that (a) this Agreement has been duly executed and delivered and constitutes a valid and binding agreement enforceable against such Party in accordance with its terms, (b) no authorization or approval from any third party is required in connection with such Party’s execution, delivery, or performance of this Agreement, and (c) the execution, delivery, and performance of this Agreement does not violate the laws of any jurisdiction or the terms or conditions of any other agreement to which it is a party or by which it is otherwise bound.

**11.2** **Compliance with Laws.** Licensee represents and warrants that it will (a) use the WU Intellectual Property only to exploit the license rights granted in Section 2 in accordance with the provisions of this Agreement and with such laws, rules, regulations, government permissions and standards as may be applicable thereto in the Authorized Use, and (b) otherwise comply with all laws, rules, regulations, government permissions and standards as may be applicable to Licensee with respect to the performance by Licensee of its obligations hereunder.

**11.3 Additional Warranties of Licensee.** Licensee represents and warrants that (a) it has obtained the insurance coverage required by Article 14 below, and (b) there is no pending litigation and no threatened claims against it that could impair its ability or capacity to perform and fulfill its duties and obligations under this Agreement.

* 1. **Additional Warranties of WU.** WU represents and warrants that, as of the Effective Date (a) it owns all right, title and interest in the WU Intellectual Property; and (b) it has received no notice of any third party claims against WU challenging WU’s ownership or control of the WU Intellectual Property.

**12. DISCLAIMER AND LIMITATION OF LIABILITIES**

NOTWITHSTANDING ANYTHING HEREIN TO THE CONTRARY, EVERYTHING PROVIDED BY WU UNDER THIS AGREEMENT IS UNDERSTOOD TO BE EXPERIMENTAL IN NATURE AND IS PROVIDED WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION, WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, TRADEMARK, COPYRIGHT OR ANY OTHER THIRD-PARTY RIGHT. WU MAKES NO WARRANTIES REGARDING THE QUALITY, ACCURACY, OR ANY OTHER ASPECT OF THE WU INTELLECTUAL PROPERTY OR ANY USE THEREOF. IN NO EVENT SHALL WU OR LICENSEE BE LIABLE FOR ANY INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF THE PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES. EXCEPT FOR THEIR RESPECTIVE INDEMNITY OBLIGATIONS, EACH PARTY’S AGGREGATE LIABILITY TO THE OTHER UNDER THIS AGREEMENT SHALL NOT EXCEED THE PAYMENTS MADE OR PAYMENTS DUE UNDER THIS AGREEMENT, RESPECTIVELY.

1. **INDEMNIFICATION**

**13.1** Except to the extent prohibited by law Licensee agrees to indemnify, defend and hold harmless WU, and each of its present and former trustees, faculty, staff, employees, students, directors, officers, agents, successors and assigns (each a “WU Indemnitee”) from and against any and all judgments, losses, expenses, damages and/or liabilities (including, without limitation, any and all attorneys’ and expert witness fees and court costs), that a WU Indemnitee may incur from any and all claims, suits, actions and/or proceedings (collectively, “Claims”) due to or arising out of the use of WU Intellectual Property by Licensee or any third party using WU Intellectual Property on behalf of Licensee.

**13.2** Obligations set forth in this section shall survive termination of this Agreement, shall continue even after assignment of rights and responsibilities, and shall not be limited by any provision of this Agreement outside this section. WU shall: (a) give Licensee prompt written notice of the Claim; (b) cooperate with the Licensee, at Licensee’s expense, in connection with the defense and settlement of the Claim; and (c) not settle or compromise the Claim without the written consent of the Licensee, which shall not be unreasonably withheld. Licensee may satisfy its duty to indemnify for Fees by accepting an irrevocable duty to defend the Claim on behalf of WU without a reservation of rights, at which time Licensee shall be entitled to conduct and direct the defense of WU against such Claim using attorneys of its own selection; for all other Claims, WU shall be entitled to conduct and direct its own defense and that of other WU Indemnitees using attorneys of its own selection with Fees subject to the Licensee’s ongoing obligation to indemnify for Fees.

1. **INSURANCE**

Throughout the Term of this Agreement and for a period of five (5) years thereafter, Licensee shall obtain and maintain comprehensive general liability self-insurance, or insurance with carrier(s) having at least A.M. Best ratings/class sizes of A/VII, and in the following minimum annual limits: $2,000,000 per occurrence and $5,000,000 in the aggregate.

# 15. TERM AND TERMINATION

# 15.1 Term. This Agreement shall become effective on the Effective Date and shall continue in effect between WU and Licensee, for three (3) years or until terminated by either Party as provided herein.

**15.2 Termination.** WU may terminate this Agreement and the license granted herein if Licensee breaches any of the material terms of this Agreement and fails to cure the breach, to the reasonable satisfaction of WU, within twenty (20) days of the date on which Licensee receives notice of the breach.

**15.3 Duties Upon Termination.** Upon termination of this Agreement for any reason, Licensee shall cease all use of the WU Intellectual Property and Confidential Information. Licensee shall return to WU or destroy, at WU’s discretion, all copies and embodiments of the WU Intellectual Property and Confidential Information in its possession, custody, or control. Upon WU’s request, Licensee will furnish a written certificate of compliance with the provisions of this Section 15.3 with such certification being signed by an officer of Licensee.

**16. GENERAL PROVISIONS**

**16.1** **Import/Export Controls.** In performing their respective obligations under the Agreement, the Parties will comply with all applicable import and export control and asset control laws, regulations, and orders, as they may be amended from time to time. WU is providing no representation regarding the export control status or classification of any information or materials provided hereunder.

**16.2** **Entire Agreement; Amendment.** This Agreement embodies the entire understanding of the parties and supersedes all other past and present communications and agreements relating to the subject matter. No amendment or modification of this Agreement shall be valid unless made in writing and signed by authorized representatives of both parties.

**16.3** **Governing Law**. This Agreement shall be governed by and construed in accordance with the laws of the State of Missouri, without regard to its rules or procedures involving conflicts of laws.

**16.4** **Survival.** Each provision of this Agreement that would by its nature or terms survive, shall survive any termination or expiration of this Agreement, regardless of the cause. Such provisions include, without limitation, Sections 4, 10, 11, 12, and 13.

**16.5** **Notices.** Notices pursuant to this Agreement shall be to the following contacts and are effective when sent if sent by a commercial carrier’s overnight delivery service or when received if sent otherwise:

##### **For Washington University: For Licensee**

Office of Technology Management \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Attn: Director \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

**Mail:** Attn: \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

660 S. Euclid Avenue

Campus Box 8013

St. Louis, MO 63110

**Courier:**

4240 Duncan Avenue

Suite 110

St. Louis, MO 63110

**16.6** **Assignment.** This Agreement is binding upon and inures to the benefit of the Parties and their successors, but this Agreement may not be assigned by either Party without the prior written consent of the other Party.

**16.7** **Construction.** The recitals and preamble to this Agreement, if any, are hereby incorporated as an integral part of this Agreement as if restated herein in full. Headings are included for convenience and reference only and are not incorporated as an integral part of this Agreement. This Agreement may be executed in any number of counterparts each of which shall be deemed an original and as executed shall constitute one agreement, binding on both parties, even though both parties do not sign the same counterpart.

**16.8** **Relationship of the Parties.** Each Party is an independent contractor and not a partner or agent of the other Party. This Agreement will not be interpreted or construed as creating or evidencing any partnership or agency between the Parties or as imposing any partnership or agency obligation or liability upon either Party. Further, neither Party is authorized to, and will not, enter into or incur any agreement, contract, commitment, obligation or liability in the name of or otherwise on behalf of the other Party.

**16.9** **Severability.** If any provision in this Agreement is held invalid, illegal, or unenforceable in any respect, such holding shall not affect any other provisions of this Agreement, and this Agreement shall be construed as if it had never contained the invalid, illegal, or unenforceable provisions.

**16.10** **Remedies.** The failure of either Party to insist upon or enforce strict performance by the other Party of any provision of this Agreement, or to exercise any right or remedy under this Agreement will not be interpreted or construed as a waiver or relinquishment of that Party's right to assert or rely upon any such provision, right or remedy in that or any other instance; rather, the same will be and remain in full force and effect. All rights and remedies under this Agreement are cumulative of every other such right or remedy and may be exercised concurrently or separately from time-to-time.

**16.11** **Use of Names.** Neither Party may use the trademarks or name of the other Party or its employees for any commercial, advertisement, or promotional purposes without the prior written consent of an authorized corporate office of the other. If either Party is required by law, governmental regulation, or its own authorship or conflict of interest policies to disclose its relationship with the other Party, including, but not limited to, in SEC filings, scientific publications or grant submissions, it shall provide the other Party with a copy of the disclosure.

**16.12** **Force Majeure.** Neither WU nor Licensee will be liable for failure of or delay in performing obligations set forth in this Agreement, and neither will be deemed in breach of its obligations, other than for payments due and owing hereunder, if such failure or delay is due to natural disasters or other causes reasonably beyond the control of a Party and reasonable notice of the delay is provided to the other Party.

**16.13** **WU Personnel.** Licensee agrees that for all WU faculty or staff members who serve Licensee in the capacity of consultant, officer, employee, board member, advisor, or otherwise through a personal relationship with Licensee (a “Consultant”) (i) such Consultant shall serve the Licensee in his or her individual capacity, as an independent contractor, and not as an agent, employee or representative of WU; (ii) WU exercises no authority or control over such Consultant while acting in such capacity; (iii) WU receives no benefit from such activity; (iv) neither Licensee nor the Consultant may use WU resources in the course of such service; (v) WU makes no representations or warranties regarding such service and otherwise assumes no liability or obligation in connection with any such work or service undertaken by such Consultant; and (vi) any breach, error, or omission by a Consultant acting in the capacity set forth in this paragraph shall not be imputed or otherwise attributed to WU, and shall not constitute a breach of this Agreement by WU.

**16.14** **Further Acts.** Each Party shall, at the reasonable request of the other, execute and deliver to the other such instruments and/or documents and shall take such actions as may be required to more effectively carry out the terms of this Agreement.

**16.15 Counterparts.** This Agreement may be executed in multiple counterparts, which when taken together shall comprise a binding agreement. If this Agreement is signed in counterparts, no signatory hereto will be bound until all Parties have duly executed, or caused to be duly executed, a counterpart of this Agreement. Each Party may rely on facsimile or electronically transmitted signature pages as if such facsimile or electronically transmitted pages were originals.

**[SIGNATURE PAGE FOLLOWS]**

**The signatures of the undersigned indicate that they have read, understand and agree with the terms of this Agreement and have the authority to execute this Agreement on behalf of their represented Party and to bind their Party to all the terms of this Agreement.**

 **WASHINGTON UNIVERSITY LICENSEE**

Signature: Signature:

Name: Name:

Title: Title:

 Date: Date:

**EXHIBIT A**

**WU INTELLECTUAL PROPERTY**

 “Your Disease Risk Improvements” (Tech. No. 007671), and “Your Disease Risk” (Tech. No. 007693), including questionnaire wording and logic, as well as risk calculation and population prevalence (U.S.) spreadsheets and algorithms for each disease risk tool (“YDR Tool”) as requested in Exhibit C (Separately Provided)

**EXHIBIT B**

**Features of DISEASE RISK ASSESSMENT TOOLS**

Disease Risk Assessment Tools shall not substantially resemble the look, feel, appearance, functionality, and specific purpose of the Your Disease Risk (YDR) Website. Specifically, Disease Risk Assessment Tools shall not include the following features of the YDR Website:

* The overall appearance of the YDR Website, including but not limited to the look, feel, color scheme, designs, logos, color-coded risk graphic, placement of elements on pages.
* The full text of questionnaires and messages.
* The results page, with its graphic that provides  both relative risk ("your risk" and a personal absolute risk ("your lowest possible risk"); risk manipulation function (which allows users to see what their risk could be if they made certain changes); and reinforcing messages ("keep up the good work")
* The specific list of disease tools (12 cancers - bladder, breast, cervical, colon, kidney, lung, melanoma, ovarian, pancreatic, prostate, stomach, uterine; plus heart disease, stroke, diabetes, and osteoporosis) in the same order that is listed on the YDR Website.

**Exhibit C**

**PROTOCOL**

|  |
| --- |
| Purpose:\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_Where will the Disease Risk Assessment Tools be used? \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_­­­­\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_What method will you use to display Disease Risk Assessment Tools to end-users? (select all that apply below)\_\_\_Paper copy \_\_\_ Audio \_\_\_ On-screen local administration \_\_\_ On-line web administration\_\_\_ other, please describe:\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Place an “X” next to each version of the questionnaire that is requested below:\_\_\_\_ Bladder Cancer \_\_\_\_Pancreatic Cancer \_\_\_\_Prostate Cancer \_\_\_\_\_Stomach Cancer\_\_\_\_Breast Cancer \_\_\_\_Uterine Cancer \_\_\_\_Kidney Cancer \_\_\_\_\_Cervical Cancer \_\_\_\_Lung Cancer \_\_\_\_Melanoma \_\_\_\_Ovarian Cancer \_\_\_\_\_Colon Cancer\_\_\_\_Heart Disease \_\_\_\_Stroke \_\_\_\_ Diabetes  |